Candriam Luxembourg S.C.A. Acquires New Holdings in AstraZeneca plc (NYSE:AZN)

Candriam Luxembourg S.C.A. acquired a new stake in AstraZeneca plc (NYSE:AZN) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 100,016 shares of the company’s stock, valued at approximately $4,987,000.

Other hedge funds also recently modified their holdings of the company. Fisher Asset Management LLC increased its position in AstraZeneca by 2.2% in the 3rd quarter. Fisher Asset Management LLC now owns 16,261,961 shares of the company’s stock worth $724,796,000 after buying an additional 357,670 shares during the period. Parametric Portfolio Associates LLC increased its position in AstraZeneca by 7.9% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 2,987,152 shares of the company’s stock worth $133,137,000 after buying an additional 217,690 shares during the period. Russell Investments Group Ltd. increased its position in AstraZeneca by 6.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,958,492 shares of the company’s stock worth $87,492,000 after buying an additional 123,962 shares during the period. ZWJ Investment Counsel Inc. increased its position in AstraZeneca by 1.2% in the 3rd quarter. ZWJ Investment Counsel Inc. now owns 737,044 shares of the company’s stock worth $32,850,000 after buying an additional 8,968 shares during the period. Finally, CIBC Private Wealth Group LLC increased its position in AstraZeneca by 1.5% in the 4th quarter. CIBC Private Wealth Group LLC now owns 630,029 shares of the company’s stock worth $31,413,000 after buying an additional 9,390 shares during the period. 17.44% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have commented on the company. Liberum Capital reaffirmed a “hold” rating on shares of AstraZeneca in a research report on Thursday, October 24th. Svb Leerink began coverage on AstraZeneca in a research report on Friday, November 22nd. They set an “outperform” rating on the stock. Leerink Swann began coverage on AstraZeneca in a research report on Friday, November 22nd. They set an “outperform” rating and a $57.00 price objective on the stock. Cowen restated an “outperform” rating and set a $55.00 price objective (up from $48.00) on shares of AstraZeneca in a research report on Monday, December 2nd. Finally, ValuEngine upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, February 4th. Four analysts have rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. AstraZeneca has an average rating of “Hold” and an average target price of $50.35.

AZN opened at $47.85 on Friday. The stock has a market cap of $129.43 billion, a PE ratio of 23.38, a P/E/G ratio of 1.48 and a beta of 0.48. The company has a current ratio of 0.92, a quick ratio of 0.70 and a debt-to-equity ratio of 1.29. AstraZeneca plc has a 1 year low of $36.83 and a 1 year high of $51.55. The stock’s 50 day simple moving average is $49.88 and its 200-day simple moving average is $46.88.

AstraZeneca Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Further Reading: Dividend Aristocrat Index

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.